Free Medical Oncology CE/CME

23rd Annual School of Breast Oncology® Curriculum

Joyce O’Shaughnessy, MD

Community Oncology Connections™: Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Webinar Series

Project ECHO®: From Evidence to Action: Integrating New ADC Approaches to Optimize Treatment Sequencing in mTNBC

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Y…

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne…

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FA…

Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

Andrew A. Lane, MD, PhD; Marlise Luskin, MD, MSCE; Kendra Sweet, MD

OncoBytes Microlearning Pathways: New Directions in Triple-Negative Breast Cancer – Practice-Ready Updates and Expert Insights Into Recent Therapeutic Breakthroughs – Nursing (Part 2)

OncoBytes Microlearning Pathways: New Directions in Triple-Negative Breast Cancer – Practice-Ready Updates and Expert Insights Into Recent Therapeutic Breakthroughs – Nursing (Part 1)

William J. Gradishar, MD, FASCO, FACP; Kamel Abou Hussein, MD

Introducing Novel Treatment Paradigms for Metastatic TNBC

Aditya Bardia, MD, MPH, FASCO; Alexis LeVee, MD

Key Considerations for Health Equity and Patient-Centered Care in TNBC

Aditya Bardia, MD, MPH, FASCO; Kathryn E. Post, PhD, ANP-BC

Current Approaches and Future Directions for Early-Stage TNBC

Nour Abuhadra, MD; Antonio Giordano, MD, PhD

From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC

William J. Gradishar, MD, FASCO, FACP; Kamel Abou Hussein, MD

25th Annual International Congress on the Future of Breast Cancer® West

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Solange Peters, MD, PhD; Myung-Ju Ahn, MD, PhD; Benjamin P. Levy, MD; Steph…

Advancing Access to High-Quality, Biomarker-Guided Care for All Patients With mNSCLC

Narjust Florez, MD, FASCO; Darren Luon, PharmD, BCOP; Dipesh Uprety, MD; Co…

Community Practice Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma

Geoffrey Ku, MD; Sunnie S. Kim, MD

Satellite Symposia at the Annual Radiation Oncology Meeting

September 27-28, 2026

25th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Project ECHO®: Extending the Impact of CAR T—Practical Approaches to Long-Term Care in the Community

Jesús G. Berdeja, MD; Nicholas Barkemeyer, PA-C, MPAS; Michael Byrne, DO, F…

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Kurt C. Demel, MD, MBA; Sara A. Hurvitz, MD, FACP

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care

August 20, 2026

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

Syma Iqbal, MD; Benjamin Scheier, MD

Project ECHO®: Navigating CRS and ICANS Related to CAR T-Cell Therapy: Prevention, Grading, and Management in Practice

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP; Kyle T. Roberts, PA-C

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

Project ECHO®: Building Bridges in CAR T Care: Collaborative Pathways to Improve Patient Access and Navigate Referrals

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP; Katie Marcucci, DMSc, PA-C, …

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

John O. Mascarenhas, MD; Claire Harrison, MD, DM, FRCP, FRCPath; Raajit Ram…

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

Webinar Series

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Community Practice Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO; Kamel Abou Hussein, MD

BURST CME™ Activity 2: Oral SERD Monotherapy: Understanding the Evidence Base

Adam Brufsky, MD, PhD; Manali Bhave, MD

Project ECHO®: CAR T in Practice: Identifying Eligible Patients Across Hematologic Malignancies

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Ruben A. Mesa, MD, FACP; Andrew Kuykendall, MD; Sangeetha Venugopal, MD, MS

BURST CME™ Activity 1: Foundations of Endocrine Resistance and Oral SERDs in HR+/HER2– Metastatic Breast Cancer

Adam Brufsky, MD, PhD; Manali Bhave, MD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisbe…

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; Ja…

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Benjamin P. Levy, MD; Sarah Goldberg, MD, MPH; Jacob Sands, MD; Helena Yu, …

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us

Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD…

Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care Models

February 6, 2027

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham MD, FACP; Paolo Taran…

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; Paula A. Ugalde Figueroa, …

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Gabriela Hobbs, MD; Rami Komrokji, MD; Douglas A. Tremblay, MD

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, …

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Ghassan Abou-Alfa, MD, MBA; Riad Salem, MD, MBA; Rachna Shroff, MD, MS, FAS…

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, PhD